CA2803620A1

CA2803620A1 - Heterocyclic compounds and their uses

Heterocyclic compounds and their uses Download PDF

Info

Publication number: CA2803620A1
Authority: CA; Canada
Prior art keywords: 4alk; mmol; substituted; halo; 6alknr
Prior art date: 2010-06-30
Legal status : Abandoned

Application number

CA2803620A

Other languages

English (en)

French (fr)

Inventor

Paul John Dransfield

Felix Gonzalez Lopez De Turiso

Vatee Pattaropong

Jillian L. Simard

Current Assignee

Amgen Inc

Original Assignee

Amgen Inc

Priority date

2010-06-30

Filing date

2011-06-30

Publication date

2012-01-05

2011-06-30 Application filed by Amgen Inc filed Critical Amgen Inc

2012-01-05 Publication of CA2803620A1 publication Critical patent/CA2803620A1/en

Status Abandoned legal-status Critical Current

Links

150000002391 heterocyclic compounds Chemical class 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 34
230000000694 effects Effects 0.000 claims abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
230000002757 inflammatory effect Effects 0.000 claims abstract description 14
230000001404 mediated effect Effects 0.000 claims abstract description 13
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
208000035475 disorder Diseases 0.000 claims abstract description 12
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 10
201000004681 Psoriasis Diseases 0.000 claims abstract description 8
201000008482 osteoarthritis Diseases 0.000 claims abstract description 8
201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 7
230000001419 dependent effect Effects 0.000 claims abstract description 6
208000026935 allergic disease Diseases 0.000 claims abstract description 5
206010020751 Hypersensitivity Diseases 0.000 claims abstract description 4
230000004968 inflammatory condition Effects 0.000 claims abstract description 4
206010027654 Allergic conditions Diseases 0.000 claims abstract description 3
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims abstract description 3
206010020853 Hypertonic bladder Diseases 0.000 claims abstract description 3
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims abstract description 3
208000034189 Sclerosis Diseases 0.000 claims abstract description 3
208000021386 Sjogren Syndrome Diseases 0.000 claims abstract description 3
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims abstract description 3
208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims abstract description 3
201000000448 autoimmune hemolytic anemia Diseases 0.000 claims abstract description 3
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims abstract description 3
230000001684 chronic effect Effects 0.000 claims abstract description 3
208000030533 eye disease Diseases 0.000 claims abstract description 3
230000009610 hypersensitivity Effects 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 86
-1 morpholino, piperazinyl Chemical group 0.000 claims description 51
125000005843 halogen group Chemical group 0.000 claims description 48
229920006395 saturated elastomer Polymers 0.000 claims description 38
125000001424 substituent group Chemical group 0.000 claims description 35
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
125000004429 atom Chemical group 0.000 claims description 23
125000004093 cyano group Chemical group *C#N 0.000 claims description 20
125000002950 monocyclic group Chemical group 0.000 claims description 20
125000004432 carbon atom Chemical group C* 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 17
125000000464 thioxo group Chemical group S=* 0.000 claims description 15
125000002619 bicyclic group Chemical group 0.000 claims description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
229910052760 oxygen Inorganic materials 0.000 claims description 9
125000000623 heterocyclic group Chemical group 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 7
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000004434 sulfur atom Chemical group 0.000 claims description 6
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 57
210000003719 b-lymphocyte Anatomy 0.000 abstract description 24
210000001744 T-lymphocyte Anatomy 0.000 abstract description 9
206010006187 Breast cancer Diseases 0.000 abstract description 6
208000026310 Breast neoplasm Diseases 0.000 abstract description 6
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract description 4
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract description 4
208000031261 Acute myeloid leukaemia Diseases 0.000 abstract description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract description 3
206010061218 Inflammation Diseases 0.000 abstract description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 abstract description 3
208000014767 Myeloproliferative disease Diseases 0.000 abstract description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract description 3
230000004054 inflammatory process Effects 0.000 abstract description 3
208000032839 leukemia Diseases 0.000 abstract description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
208000003950 B-cell lymphoma Diseases 0.000 abstract 1
101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 abstract 1
101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 abstract 1
101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 abstract 1
208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000025747 Rheumatic disease Diseases 0.000 abstract 1
101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 abstract 1
102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 abstract 1
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 125
229910052739 hydrogen Inorganic materials 0.000 description 111
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 89
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 66
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
235000019439 ethyl acetate Nutrition 0.000 description 62
210000004027 cell Anatomy 0.000 description 61
238000006243 chemical reaction Methods 0.000 description 60
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 55
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 55
239000000243 solution Substances 0.000 description 55
238000001819 mass spectrum Methods 0.000 description 41
108091007960 PI3Ks Proteins 0.000 description 37
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
238000000132 electrospray ionisation Methods 0.000 description 33
239000007787 solid Substances 0.000 description 33
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
239000000047 product Substances 0.000 description 30
108010029485 Protein Isoforms Proteins 0.000 description 26
102000001708 Protein Isoforms Human genes 0.000 description 26
229910052943 magnesium sulfate Inorganic materials 0.000 description 26
235000019341 magnesium sulphate Nutrition 0.000 description 26
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 25
238000002360 preparation method Methods 0.000 description 25
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
241000699670 Mus sp. Species 0.000 description 23
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 22
UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 21
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
230000002829 reductive effect Effects 0.000 description 20
238000004440 column chromatography Methods 0.000 description 19
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
239000012044 organic layer Substances 0.000 description 17
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
238000003556 assay Methods 0.000 description 16
239000000872 buffer Substances 0.000 description 16
230000004913 activation Effects 0.000 description 15
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
239000012267 brine Substances 0.000 description 14
239000003814 drug Substances 0.000 description 14
238000001914 filtration Methods 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
239000000651 prodrug Substances 0.000 description 14
229940002612 prodrug Drugs 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 13
150000002148 esters Chemical class 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
239000013058 crude material Substances 0.000 description 12
238000005160 1H NMR spectroscopy Methods 0.000 description 11
150000001412 amines Chemical class 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
239000002253 acid Substances 0.000 description 10
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 10
239000000908 ammonium hydroxide Substances 0.000 description 10
229910052786 argon Inorganic materials 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
239000002609 medium Substances 0.000 description 10
230000011664 signaling Effects 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
108010044467 Isoenzymes Proteins 0.000 description 9
SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
229940079593 drug Drugs 0.000 description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
230000006870 function Effects 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
125000003710 aryl alkyl group Chemical group 0.000 description 8
239000012043 crude product Substances 0.000 description 8
238000000605 extraction Methods 0.000 description 8
229940113083 morpholine Drugs 0.000 description 8
230000035772 mutation Effects 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
108091000080 Phosphotransferase Proteins 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
150000003905 phosphatidylinositols Chemical class 0.000 description 7
102000020233 phosphotransferase Human genes 0.000 description 7
229910000027 potassium carbonate Inorganic materials 0.000 description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
239000000377 silicon dioxide Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 6
241000283707 Capra Species 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
238000003016 alphascreen Methods 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
239000002808 molecular sieve Substances 0.000 description 6
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 6
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
238000000926 separation method Methods 0.000 description 6
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
238000010186 staining Methods 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
GYCADYKNHVDHLC-UHFFFAOYSA-N 4-chloro-5,7-difluoro-3-methyl-2-pyridin-2-ylquinoline Chemical compound CC1=C(Cl)C2=C(F)C=C(F)C=C2N=C1C1=CC=CC=N1 GYCADYKNHVDHLC-UHFFFAOYSA-N 0.000 description 5
IQVUIYGZPSSGIV-UHFFFAOYSA-N 4-chloro-7-fluoro-3-methyl-2-pyridin-2-ylquinoline Chemical compound CC1=C(Cl)C2=CC=C(F)C=C2N=C1C1=CC=CC=N1 IQVUIYGZPSSGIV-UHFFFAOYSA-N 0.000 description 5
150000005653 4-chloroquinolines Chemical class 0.000 description 5
CIJMXUYBVAGYQB-UHFFFAOYSA-N 5-bromo-2-morpholin-4-ylpyrimidin-4-amine Chemical compound C1=C(Br)C(N)=NC(N2CCOCC2)=N1 CIJMXUYBVAGYQB-UHFFFAOYSA-N 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
102000038030 PI3Ks Human genes 0.000 description 5
108090000315 Protein Kinase C Proteins 0.000 description 5
102000003923 Protein Kinase C Human genes 0.000 description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
239000011324 bead Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
238000012552 review Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 5
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 5
KWVNKWCJDAWNAE-UHFFFAOYSA-N 2,3-dichloroquinoline Chemical class C1=CC=C2N=C(Cl)C(Cl)=CC2=C1 KWVNKWCJDAWNAE-UHFFFAOYSA-N 0.000 description 4
OKOXMEUPMHJPQL-UHFFFAOYSA-N 3-anilino-2-oxopropanoic acid Chemical class OC(=O)C(=O)CNC1=CC=CC=C1 OKOXMEUPMHJPQL-UHFFFAOYSA-N 0.000 description 4
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000005754 cellular signaling Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000013461 design Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000013508 migration Methods 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
XBYHXIGSLGISGR-UHFFFAOYSA-N n-(6-amino-2-morpholin-4-ylpyrimidin-4-yl)acetamide Chemical compound CC(=O)NC1=CC(N)=NC(N2CCOCC2)=N1 XBYHXIGSLGISGR-UHFFFAOYSA-N 0.000 description 4
HYEHVCSWSJLFFC-UHFFFAOYSA-N n-[6-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidin-4-yl]acetamide Chemical compound N=1C(N2CCOCC2)=NC(NC(=O)C)=CC=1NC(C1=CC=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 HYEHVCSWSJLFFC-UHFFFAOYSA-N 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
150000003248 quinolines Chemical class 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
SZPQTEWIRPXBTC-KFOWTEFUSA-N 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H]1O SZPQTEWIRPXBTC-KFOWTEFUSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
IZHATATVLOKVET-UHFFFAOYSA-N 2-chloro-9-(oxan-2-yl)purin-6-amine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1C1CCCCO1 IZHATATVLOKVET-UHFFFAOYSA-N 0.000 description 3
AJVVTDXEOKDRFO-UHFFFAOYSA-N 2-morpholin-4-yl-9-(oxan-2-yl)purin-6-amine Chemical compound C1=NC=2C(N)=NC(N3CCOCC3)=NC=2N1C1CCCCO1 AJVVTDXEOKDRFO-UHFFFAOYSA-N 0.000 description 3
DLLZTJATHZHWTI-UHFFFAOYSA-N 4-[(5,7-difluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidine-5-carboxylic acid Chemical compound C12=C(F)C=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(C(=CN=1)C(O)=O)=NC=1N1CCOCC1 DLLZTJATHZHWTI-UHFFFAOYSA-N 0.000 description 3
COHDJNHBEACCIG-UHFFFAOYSA-N 4-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-n-methyl-6-morpholin-4-ylpyridine-2-carboxamide Chemical compound C=1C(N2CCOCC2)=NC(C(=O)NC)=CC=1NC(C1=CC=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 COHDJNHBEACCIG-UHFFFAOYSA-N 0.000 description 3
VZIOMKJXBBTECU-UHFFFAOYSA-N 4-chloro-n-methyl-6-morpholin-4-ylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC(Cl)=CC(N2CCOCC2)=N1 VZIOMKJXBBTECU-UHFFFAOYSA-N 0.000 description 3
JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
229960000549 4-dimethylaminophenol Drugs 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
UERUGHGRCQCPMG-UHFFFAOYSA-N 5,7-difluoro-3-methyl-n-(2-morpholin-4-ylpyrimidin-4-yl)-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=C(F)C=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(N=1)=CC=NC=1N1CCOCC1 UERUGHGRCQCPMG-UHFFFAOYSA-N 0.000 description 3
IPWCJBFJTANBLM-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-2-morpholin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=CC(C=2C(=NC(=NC=2)N2CCOCC2)N)=C1 IPWCJBFJTANBLM-UHFFFAOYSA-N 0.000 description 3
OIXRKKUGSLLVHI-UHFFFAOYSA-N 5-[4-(difluoromethoxy)phenyl]-2-morpholin-4-ylpyrimidin-4-amine Chemical compound NC1=NC(N2CCOCC2)=NC=C1C1=CC=C(OC(F)F)C=C1 OIXRKKUGSLLVHI-UHFFFAOYSA-N 0.000 description 3
DWNRPGMPGOMZQZ-UHFFFAOYSA-N 6-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidine-4-carbonitrile Chemical compound C12=CC=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(N=1)=CC(C#N)=NC=1N1CCOCC1 DWNRPGMPGOMZQZ-UHFFFAOYSA-N 0.000 description 3
DMKDOGBMEWJMGF-UHFFFAOYSA-N 6-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-n-methyl-4-morpholin-4-ylpyridine-2-carboxamide Chemical compound N=1C(C(=O)NC)=CC(N2CCOCC2)=CC=1NC(C1=CC=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 DMKDOGBMEWJMGF-UHFFFAOYSA-N 0.000 description 3
PNCOPXIDIBVJJE-UHFFFAOYSA-N 6-amino-2-morpholin-4-ylpyrimidine-4-carbonitrile Chemical compound NC1=CC(C#N)=NC(N2CCOCC2)=N1 PNCOPXIDIBVJJE-UHFFFAOYSA-N 0.000 description 3
CAPWCRRKZOKFTE-UHFFFAOYSA-N 6-chloro-2-morpholin-4-ylpyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(N2CCOCC2)=N1 CAPWCRRKZOKFTE-UHFFFAOYSA-N 0.000 description 3
HJGVMGZLILXQNW-UHFFFAOYSA-N 6-chloro-4-morpholin-4-ylpyridine-2-carboxylic acid Chemical compound ClC1=NC(C(=O)O)=CC(N2CCOCC2)=C1 HJGVMGZLILXQNW-UHFFFAOYSA-N 0.000 description 3
MJFLWAIINOJCIJ-UHFFFAOYSA-N 6-chloro-n-methyl-4-morpholin-4-ylpyridine-2-carboxamide Chemical compound ClC1=NC(C(=O)NC)=CC(N2CCOCC2)=C1 MJFLWAIINOJCIJ-UHFFFAOYSA-N 0.000 description 3
FHLLNKDMACKQBN-UHFFFAOYSA-N 7-fluoro-3-methyl-n-(2-morpholin-4-yl-7h-purin-6-yl)-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=CC=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(C=1N=CNC=1N=1)=NC=1N1CCOCC1 FHLLNKDMACKQBN-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102100025137 Early activation antigen CD69 Human genes 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102000004315 Forkhead Transcription Factors Human genes 0.000 description 3
108090000852 Forkhead Transcription Factors Proteins 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940124639 Selective inhibitor Drugs 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
150000001448 anilines Chemical class 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
XYLZJYDGUZKDCG-UHFFFAOYSA-N ditert-butyl 2-[(6-amino-2-morpholin-4-ylpyrimidin-4-yl)carbamoyl]propanedioate Chemical compound CC(C)(C)OC(=O)C(C(=O)OC(C)(C)C)C(=O)NC1=CC(N)=NC(N2CCOCC2)=N1 XYLZJYDGUZKDCG-UHFFFAOYSA-N 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
JUWSURXCRLIMJE-UHFFFAOYSA-N ethyl 2-morpholin-4-yl-6-oxo-1h-pyrimidine-5-carboxylate Chemical compound N1C(=O)C(C(=O)OCC)=CN=C1N1CCOCC1 JUWSURXCRLIMJE-UHFFFAOYSA-N 0.000 description 3
ADYQXKGDZBFHKP-UHFFFAOYSA-N ethyl 4-[(4-methoxyphenyl)methylamino]-2-morpholin-4-ylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(N2CCOCC2)N=C1NCC1=CC=C(OC)C=C1 ADYQXKGDZBFHKP-UHFFFAOYSA-N 0.000 description 3
LFUDBQDKNCOTQO-UHFFFAOYSA-N ethyl 4-amino-2-morpholin-4-ylpyrimidine-5-carboxylate Chemical compound N1=C(N)C(C(=O)OCC)=CN=C1N1CCOCC1 LFUDBQDKNCOTQO-UHFFFAOYSA-N 0.000 description 3
ZYIJNUYHOXXCPR-UHFFFAOYSA-N ethyl 4-chloro-2-morpholin-4-ylpyrimidine-5-carboxylate Chemical compound N1=C(Cl)C(C(=O)OCC)=CN=C1N1CCOCC1 ZYIJNUYHOXXCPR-UHFFFAOYSA-N 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000011813 knockout mouse model Methods 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
WVBPOKHRVCEYEW-UHFFFAOYSA-N methyl 4-chloro-6-morpholin-4-ylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC(Cl)=CC(N2CCOCC2)=N1 WVBPOKHRVCEYEW-UHFFFAOYSA-N 0.000 description 3
BZIZZYXEXBWRDP-UHFFFAOYSA-N methyl 6-chloro-4-morpholin-4-ylpyridine-2-carboxylate Chemical compound ClC1=NC(C(=O)OC)=CC(N2CCOCC2)=C1 BZIZZYXEXBWRDP-UHFFFAOYSA-N 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
RNZVZTAPZYGTFZ-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-5,7-difluoro-3-methyl-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=C(F)C=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC1=CC=NC(Cl)=N1 RNZVZTAPZYGTFZ-UHFFFAOYSA-N 0.000 description 3
YZAKLNHEVCYQDA-UHFFFAOYSA-N n-[3-(4-amino-2-morpholin-4-ylpyrimidin-5-yl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C(=NC(=NC=2)N2CCOCC2)N)=C1 YZAKLNHEVCYQDA-UHFFFAOYSA-N 0.000 description 3
NNSXNWXXLFETGD-UHFFFAOYSA-N n-[3-[4-[(5,7-difluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidin-5-yl]phenyl]methanesulfonamide Chemical compound C12=C(F)C=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC1=NC(N2CCOCC2)=NC=C1C1=CC=CC(NS(C)(=O)=O)=C1 NNSXNWXXLFETGD-UHFFFAOYSA-N 0.000 description 3
RKCFOCAZNQDQHC-UHFFFAOYSA-N n-[5-[4-(difluoromethoxy)phenyl]-2-morpholin-4-ylpyrimidin-4-yl]-5-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=C(F)C=CC=C2N=C(C=2N=CC=CC=2)C(C)=C1NC1=NC(N2CCOCC2)=NC=C1C1=CC=C(OC(F)F)C=C1 RKCFOCAZNQDQHC-UHFFFAOYSA-N 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000006884 silylation reaction Methods 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
239000012258 stirred mixture Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
JLGVFRVZLRIFRH-UHFFFAOYSA-N tert-butyl n-(6-cyano-2-morpholin-4-ylpyrimidin-4-yl)-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=CC(C#N)=NC(N2CCOCC2)=N1 JLGVFRVZLRIFRH-UHFFFAOYSA-N 0.000 description 3
WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
235000019798 tripotassium phosphate Nutrition 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
SUXIPCHEUMEUSV-UHFFFAOYSA-N 4-bromoquinoline Chemical class C1=CC=C2C(Br)=CC=NC2=C1 SUXIPCHEUMEUSV-UHFFFAOYSA-N 0.000 description 2
PIWDSSRIYKLKDU-UHFFFAOYSA-N 4-chloro-6-morpholin-4-ylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC(N2CCOCC2)=N1 PIWDSSRIYKLKDU-UHFFFAOYSA-N 0.000 description 2
UMUSFEOPXQLLAG-UHFFFAOYSA-N 4-morpholin-4-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(N2CCOCC2)=N1 UMUSFEOPXQLLAG-UHFFFAOYSA-N 0.000 description 2
PHDCSHVFUIPJCF-UHFFFAOYSA-N 5,7-difluoro-3-methyl-2-(4-methylpyridin-2-yl)-n-(6-morpholin-4-ylpyrazin-2-yl)quinolin-4-amine Chemical compound CC1=CC=NC(C=2C(=C(NC=3N=C(C=NC=3)N3CCOCC3)C3=C(F)C=C(F)C=C3N=2)C)=C1 PHDCSHVFUIPJCF-UHFFFAOYSA-N 0.000 description 2
JDSBFBSXXMFBRS-UHFFFAOYSA-N 5,7-difluoro-n-[5-(5-methoxypyridin-3-yl)-2-morpholin-4-ylpyrimidin-4-yl]-3-methyl-2-pyridin-2-ylquinolin-4-amine Chemical compound COC1=CN=CC(C=2C(=NC(=NC=2)N2CCOCC2)NC=2C3=C(F)C=C(F)C=C3N=C(C=2C)C=2N=CC=CC=2)=C1 JDSBFBSXXMFBRS-UHFFFAOYSA-N 0.000 description 2
PTQRJZXZMRXHBW-UHFFFAOYSA-N 6-morpholin-4-ylpyrazin-2-amine Chemical compound NC1=CN=CC(N2CCOCC2)=N1 PTQRJZXZMRXHBW-UHFFFAOYSA-N 0.000 description 2
JSMIPXVKYAWNAH-UHFFFAOYSA-N 7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-amine Chemical compound CC1=C(N)C2=CC=C(F)C=C2N=C1C1=CC=CC=N1 JSMIPXVKYAWNAH-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
108010029697 CD40 Ligand Proteins 0.000 description 2
102100032937 CD40 ligand Human genes 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
108091007958 Class I PI3Ks Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 2
108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000016267 Leptin Human genes 0.000 description 2
108010092277 Leptin Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 2
WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
BERPCVULMUPOER-UHFFFAOYSA-N Quinolinediol Chemical class C1=CC=C2NC(=O)C(O)=CC2=C1 BERPCVULMUPOER-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 2
102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 2
229940037003 alum Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229940099352 cholate Drugs 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000036267 drug metabolism Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
ZAGAAHSCMKFJQS-UHFFFAOYSA-N ethyl 4-[(5,7-difluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(N2CCOCC2)N=C1NC(C1=C(F)C=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 ZAGAAHSCMKFJQS-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
150000004820 halides Chemical group 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
150000003949 imides Chemical class 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
229940039781 leptin Drugs 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
JTLNCBZYKHUFHP-UHFFFAOYSA-N n-(6-amino-5-bromo-2-morpholin-4-ylpyrimidin-4-yl)acetamide Chemical compound NC1=C(Br)C(NC(=O)C)=NC(N2CCOCC2)=N1 JTLNCBZYKHUFHP-UHFFFAOYSA-N 0.000 description 2
POAPMLGHPZGUQJ-UHFFFAOYSA-N n-(6-amino-5-cyano-2-morpholin-4-ylpyrimidin-4-yl)acetamide Chemical compound NC1=C(C#N)C(NC(=O)C)=NC(N2CCOCC2)=N1 POAPMLGHPZGUQJ-UHFFFAOYSA-N 0.000 description 2
BSMDPZFQOMAVOG-UHFFFAOYSA-N n-[5-[4-(difluoromethoxy)phenyl]-2-morpholin-4-ylpyrimidin-4-yl]-5,7-difluoro-3-methyl-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=C(F)C=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC1=NC(N2CCOCC2)=NC=C1C1=CC=C(OC(F)F)C=C1 BSMDPZFQOMAVOG-UHFFFAOYSA-N 0.000 description 2
CADZUCUJVULXEC-UHFFFAOYSA-N n-[5-bromo-6-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidin-4-yl]acetamide Chemical compound BrC=1C(NC(=O)C)=NC(N2CCOCC2)=NC=1NC(C1=CC=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 CADZUCUJVULXEC-UHFFFAOYSA-N 0.000 description 2
ZTQLMYUNUVDCGD-UHFFFAOYSA-N n-[5-cyano-6-[(7-fluoro-3-methyl-2-pyridin-2-ylquinolin-4-yl)amino]-2-morpholin-4-ylpyrimidin-4-yl]acetamide Chemical compound N#CC=1C(NC(=O)C)=NC(N2CCOCC2)=NC=1NC(C1=CC=C(F)C=C1N=1)=C(C)C=1C1=CC=CC=N1 ZTQLMYUNUVDCGD-UHFFFAOYSA-N 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
150000003915 phosphatidylinositol 4,5-bisphosphates Chemical class 0.000 description 2
150000003906 phosphoinositides Chemical class 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
235000019345 sodium thiosulphate Nutrition 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000005945 translocation Effects 0.000 description 2
108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 2
108010055746 trinitrophenyl-bovine serum albumin Proteins 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
SQWZFLMPDUSYGV-POHAHGRESA-N (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=N2)C2=C1 SQWZFLMPDUSYGV-POHAHGRESA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
ASNBMEFTEPQHDX-UHFFFAOYSA-N 2,6-dichloro-9-(oxan-2-yl)purine Chemical compound C12=NC(Cl)=NC(Cl)=C2N=CN1C1CCCCO1 ASNBMEFTEPQHDX-UHFFFAOYSA-N 0.000 description 1
UPVBKNZVOJNQKE-UHFFFAOYSA-N 2,6-dichloropyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(Cl)=N1 UPVBKNZVOJNQKE-UHFFFAOYSA-N 0.000 description 1
PENWAFASUFITRC-UHFFFAOYSA-N 2-(4-chlorophenyl)imidazo[2,1-a]isoquinoline Chemical compound C1=CC(Cl)=CC=C1C1=CN(C=CC=2C3=CC=CC=2)C3=N1 PENWAFASUFITRC-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
BPFSJXBWEVRJFH-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(OC(F)F)C=C1 BPFSJXBWEVRJFH-UHFFFAOYSA-N 0.000 description 1
JTPXVCKCLBROOJ-UHFFFAOYSA-N 2-amino-6-chloropyrazine Chemical compound NC1=CN=CC(Cl)=N1 JTPXVCKCLBROOJ-UHFFFAOYSA-N 0.000 description 1
FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
LPBDZVNGCNTELM-UHFFFAOYSA-N 2-chloropyrimidin-4-amine Chemical compound NC1=CC=NC(Cl)=N1 LPBDZVNGCNTELM-UHFFFAOYSA-N 0.000 description 1
YZJSARUCMYJHNV-UHFFFAOYSA-N 2-dimethylsilylethyl(dimethyl)silane Chemical group C[SiH](C)CC[SiH](C)C YZJSARUCMYJHNV-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
NOLAFMPNQBTXTA-UHFFFAOYSA-N 4-chloro-5,7-difluoro-3-methyl-2-(4-methylpyridin-2-yl)quinoline Chemical compound CC1=CC=NC(C=2C(=C(Cl)C3=C(F)C=C(F)C=C3N=2)C)=C1 NOLAFMPNQBTXTA-UHFFFAOYSA-N 0.000 description 1
JGHSFRFGHNZIPK-UHFFFAOYSA-N 4-chloro-5-fluoro-3-methyl-2-pyridin-2-ylquinoline Chemical compound CC1=C(Cl)C2=C(F)C=CC=C2N=C1C1=CC=CC=N1 JGHSFRFGHNZIPK-UHFFFAOYSA-N 0.000 description 1
DBGFGNCFYUNXLD-UHFFFAOYSA-N 4-chloropyrimidin-2-amine Chemical compound NC1=NC=CC(Cl)=N1 DBGFGNCFYUNXLD-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
QEJUSHCHCOTTPE-UHFFFAOYSA-N 4-morpholin-4-yl-1,3,5-triazin-2-amine Chemical compound NC1=NC=NC(N2CCOCC2)=N1 QEJUSHCHCOTTPE-UHFFFAOYSA-N 0.000 description 1
DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
QOWALNIZDHZTSM-UHFFFAOYSA-N 5-bromo-2-chloropyrimidin-4-amine Chemical compound NC1=NC(Cl)=NC=C1Br QOWALNIZDHZTSM-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
YSWDCMKRELCADM-UHFFFAOYSA-N 7-fluoro-3-methyl-N-(4-morpholin-4-ylpyrimidin-2-yl)-2-pyridin-2-ylquinolin-4-amine Chemical compound FC1=CC=C2C(=C(C(=NC2=C1)C1=NC=CC=C1)C)NC1=NC=CC(=N1)N1CCOCC1.FC1=CC=C2C(=C(C(=NC2=C1)C1=NC=CC=C1)C)NC1=NC=CC(=N1)N1CCOCC1 YSWDCMKRELCADM-UHFFFAOYSA-N 0.000 description 1
RXFHTGVDUDPOBD-UHFFFAOYSA-N 7-fluoro-3-methyl-n-(4-morpholin-4-yl-1,3,5-triazin-2-yl)-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=CC=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(N=1)=NC=NC=1N1CCOCC1 RXFHTGVDUDPOBD-UHFFFAOYSA-N 0.000 description 1
FTHORGNFMYOLMN-UHFFFAOYSA-N 7-fluoro-3-methyl-n-(4-morpholin-4-ylpyrimidin-2-yl)-2-pyridin-2-ylquinolin-4-amine Chemical compound C12=CC=C(F)C=C2N=C(C=2N=CC=CC=2)C(C)=C1NC(N=1)=NC=CC=1N1CCOCC1 FTHORGNFMYOLMN-UHFFFAOYSA-N 0.000 description 1
YUDXFKPYVZUMPM-UHFFFAOYSA-N 7H-purine 1H-quinazolin-2-one Chemical compound C1=NC=C2NC=NC2=N1.C1=CC=C2NC(=O)N=CC2=C1 YUDXFKPYVZUMPM-UHFFFAOYSA-N 0.000 description 1
CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
101001015038 Albizia kalkora Kunitz-type trypsin inhibitor alpha chain Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
206010003594 Ataxia telangiectasia Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091007959 Class II PI3Ks Proteins 0.000 description 1
108091007963 Class III PI3Ks Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010058002 Hypoglobulinaemia Diseases 0.000 description 1
101150088952 IGF1 gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241001197446 Mus cypriacus Species 0.000 description 1
101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
MSXMGJPCLYIVRP-UHFFFAOYSA-N O1CCN(CC1)C1=CN=CC(=N1)N.FC1=C2C(=C(C(=NC2=CC(=C1)F)C1=NC=CC(=C1)C)C)NC1=NC(=CN=C1)N1CCOCC1 Chemical compound O1CCN(CC1)C1=CN=CC(=N1)N.FC1=C2C(=C(C(=NC2=CC(=C1)F)C1=NC=CC(=C1)C)C)NC1=NC(=CN=C1)N1CCOCC1 MSXMGJPCLYIVRP-UHFFFAOYSA-N 0.000 description 1
RFBVZMOPDZUYOP-UHFFFAOYSA-N O1CCN(CC1)C1=NC(=NC=C1)N.FC1=CC=C2C(=C(C(=NC2=C1)C1=NC=CC=C1)C)NC1=NC=CC(=N1)N1CCOCC1 Chemical compound O1CCN(CC1)C1=NC(=NC=C1)N.FC1=CC=C2C(=C(C(=NC2=C1)C1=NC=CC=C1)C)NC1=NC=CC(=N1)N1CCOCC1 RFBVZMOPDZUYOP-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
101000831256 Oryza sativa subsp. japonica Cysteine proteinase inhibitor 1 Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
102000014400 SH2 domains Human genes 0.000 description 1
108050003452 SH2 domains Proteins 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
108010031271 Saccharomyces cerevisiae Proteins Proteins 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
102000042834 TEC family Human genes 0.000 description 1
108091082333 TEC family Proteins 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
MUUXBTFQEXVEEI-UHFFFAOYSA-N [2-(dimethyl-$l^{3}-silanyl)phenyl]-dimethylsilicon Chemical group C[Si](C)C1=CC=CC=C1[Si](C)C MUUXBTFQEXVEEI-UHFFFAOYSA-N 0.000 description 1
XUIQQIRLFMCWLN-UHFFFAOYSA-N [3-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC(B(O)O)=C1 XUIQQIRLFMCWLN-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
125000005042 acyloxymethyl group Chemical group 0.000 description 1
102000035181 adaptor proteins Human genes 0.000 description 1
108091005764 adaptor proteins Proteins 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
208000037884 allergic airway inflammation Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
XYXNTHIYBIDHGM-UHFFFAOYSA-N ammonium thiosulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=S XYXNTHIYBIDHGM-UHFFFAOYSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
FHCIILYMWWRNIZ-UHFFFAOYSA-N benzhydryl(chloro)silane Chemical compound C=1C=CC=CC=1C([SiH2]Cl)C1=CC=CC=C1 FHCIILYMWWRNIZ-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
KWYZNESIGBQHJK-UHFFFAOYSA-N chloro-dimethyl-phenylsilane Chemical compound C[Si](C)(Cl)C1=CC=CC=C1 KWYZNESIGBQHJK-UHFFFAOYSA-N 0.000 description 1
NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 1
LFLVWJRUOWNNAC-UHFFFAOYSA-N dicyclohexyl-[2-phenyl-1,3,5-tri(propan-2-yl)cyclohexa-2,4-dien-1-yl]phosphane Chemical group C1CCCCC1P(C1CCCCC1)C1(C(C)C)CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1 LFLVWJRUOWNNAC-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000036433 growing body Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000004217 heart function Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
102000034345 heterotrimeric G proteins Human genes 0.000 description 1
108091006093 heterotrimeric G proteins Proteins 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
102000046768 human CCL2 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Chemical group O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000006352 iso-propylthiomethyl group Chemical group [H]C([H])([H])C([H])(SC([H])([H])*)C([H])([H])[H] 0.000 description 1
125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000006229 isopropoxyethyl group Chemical group [H]C([H])([H])C([H])(OC([H])([H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000865 liniment Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000003826 marginal zone b cell Anatomy 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
HCLLOQLXKCCWLJ-UHFFFAOYSA-N methyl 2-amino-6-methylbenzoate Chemical compound COC(=O)C1=C(C)C=CC=C1N HCLLOQLXKCCWLJ-UHFFFAOYSA-N 0.000 description 1
MXHPWLMQTZILLL-UHFFFAOYSA-N methyl 4,6-dichloropyridine-2-carboxylate Chemical compound COC(=O)C1=CC(Cl)=CC(Cl)=N1 MXHPWLMQTZILLL-UHFFFAOYSA-N 0.000 description 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
XURVRZSODRHRNK-UHFFFAOYSA-N o-quinodimethane Chemical group C=C1C=CC=CC1=C XURVRZSODRHRNK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000005545 phthalimidyl group Chemical group 0.000 description 1
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
238000010791 quenching Methods 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
230000022932 ruffle assembly Effects 0.000 description 1
229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
CMQCNTNASCDNGR-UHFFFAOYSA-N toluene;hydrate Chemical compound O.CC1=CC=CC=C1 CMQCNTNASCDNGR-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
101150049389 tor2 gene Proteins 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
GMYAQHAKWKXYHG-UHFFFAOYSA-N tributylstannylformonitrile Chemical compound CCCC[Sn](CCCC)(CCCC)C#N GMYAQHAKWKXYHG-UHFFFAOYSA-N 0.000 description 1
150000008648 triflates Chemical group 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000001665 trituration Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
230000007054 vacuolar protein processing Effects 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1